Two Weeks of THC Made Rats More Sensitive to Amphetamine, Supporting Cannabis-Psychosis Link
Chronic THC treatment for 14 days made rats hypersensitive to the psychomotor effects of amphetamine after withdrawal, supporting the hypothesis that cannabis use could increase vulnerability to stimulant-induced psychosis.
Quick Facts
What This Study Found
Researchers investigated whether chronic cannabis exposure could sensitize the brain to psychosis-like effects, using amphetamine-induced behavior in rats as a model.
Three patterns emerged across different exposure conditions. Acute THC antagonized amphetamine's stimulant effects, essentially blocking the amphetamine response. During chronic THC treatment (14 days), tolerance developed to this blocking effect on some measures, while amphetamine-induced stereotypies (repetitive behaviors) were actually potentiated.
Most significantly, 24 hours after stopping 14 days of THC, rats showed sensitization to amphetamine's effects. The animals became hyperresponsive to amphetamine's ability to increase locomotion, exploration, and stereotypies. This sensitization pattern parallels what is seen in animal models of psychosis.
Since CB1 receptors are densely located in limbic and basal ganglia circuits where amphetamine enhances dopamine and serotonin, these findings supported a role for the cannabinoid system in regulating the monoaminergic circuits implicated in psychosis.
Key Numbers
Two THC doses: 0.1 and 6.4 mg/kg. Fourteen days of chronic treatment. Sensitization observed 24 hours after last dose. Three behavioral measures showing sensitization: locomotion, exploration, stereotypies.
How They Did This
Animal behavioral pharmacology in male rats. Three conditions: acute THC, chronic THC (14 days), and 24-hour withdrawal after chronic THC. Two doses of THC (0.1 and 6.4 mg/kg). Amphetamine responses measured on a hole-board assessing locomotion, exploration, inactivity, and stereotypies.
Why This Research Matters
This study provided a mechanistic model for how cannabis use might increase vulnerability to psychosis. By demonstrating that chronic THC exposure sensitizes the dopamine system, it connected two previously separate observations: clinical reports of cannabis-associated psychosis and the dopamine hypothesis of schizophrenia.
The Bigger Picture
Cross-sensitization between cannabis and dopaminergic drugs became an important line of evidence in the cannabis-psychosis literature. This animal model suggested a biological mechanism by which cannabis might not directly cause psychosis but could lower the threshold for psychosis triggered by other factors.
What This Study Doesn't Tell Us
Animal model using forced drug administration, not voluntary use. The amphetamine-psychosis model is an approximation of human psychosis, not a direct equivalent. The 24-hour withdrawal timepoint may represent an acute withdrawal state rather than lasting sensitization.
Questions This Raises
- ?Does this sensitization persist beyond 24 hours?
- ?Would it occur with intermittent rather than daily dosing?
- ?Can this animal model predict which human cannabis users are at risk for psychosis?
Trust & Context
- Key Stat:
- THC withdrawal sensitized rats to amphetamine's psychosis-like effects
- Evidence Grade:
- An animal behavioral pharmacology study with clear dose-response and temporal patterns. Provides mechanistic insight but limited by animal-to-human translation.
- Study Age:
- Published in 1999. The cannabis-psychosis connection has been extensively studied since, with both epidemiological and neuroimaging data supporting a dose-dependent risk.
- Original Title:
- Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats.
- Published In:
- European journal of pharmacology, 365(2-3), 133-42 (1999)
- Authors:
- Gorriti, M A, Rodríguez de Fonseca, F, Navarro, M, Palomo, T
- Database ID:
- RTHC-00079
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Does this mean cannabis causes psychosis?
Not directly. This study showed chronic THC sensitized the dopamine system to subsequent stimulation, suggesting cannabis could lower the threshold for psychosis without necessarily causing it alone.
What does sensitization mean?
After stopping 14 days of THC, rats responded more strongly to amphetamine than animals that had never received THC. Their dopamine system became "primed" to overreact to stimulation.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
- why-does-weed-make-you-laugh-thc-humor
- thc-and-adderall-stimulants-cannabis-brain
- thc-and-antipsychotics-complicated-relationship
Cite This Study
https://rethinkthc.com/research/RTHC-00079APA
Gorriti, M A; Rodríguez de Fonseca, F; Navarro, M; Palomo, T. (1999). Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats.. European journal of pharmacology, 365(2-3), 133-42.
MLA
Gorriti, M A, et al. "Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats.." European journal of pharmacology, 1999.
RethinkTHC
RethinkTHC Research Database. "Chronic (-)-delta9-tetrahydrocannabinol treatment induces se..." RTHC-00079. Retrieved from https://rethinkthc.com/research/gorriti-1999-chronic-delta9tetrahydrocannabinol-treatment-induces
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.